Enlivex Therapeutics (NASDAQ:ENLV) outlined the rationale for its proposed private placement with the RAIN Foundation, provided an update on its prediction-market treasury strategy and discussed clinical progress for Allocetra in knee osteoarthritis during an investor event led by Chief Executive Officer Oren Hershkovitz and Executive Chairman Shai Novik.
Management said it held the event in response to investor questions regarding the proposed financing, RAIN tokens and the company’s relationship with the RAIN Foundation. Enlivex operates what it describes as two business pillars: development of Allocetra for age-related osteoarthritis and a treasury strategy centered on the decentralized RAIN prediction-market protocol.
Proposed RAIN Foundation Investment
Under the announced agreement, the RAIN Foundation intends to purchase Enlivex shares using RAIN tokens at $6 per share, representing a premium to the market price at the time of announcement, according to Novik. If the foundation elects to fund part of the investment in cash or cash equivalents, the price would be $5 per share.
The transaction has not closed and requires shareholder approval following the filing of a proxy statement. Novik said Enlivex has the right to terminate the agreement at its sole discretion before shareholder approval is received, while the foundation does not have a corresponding termination right.
Novik also confirmed that the RAIN Foundation is already an Enlivex shareholder, having participated in the company’s November financing. He estimated that the foundation currently owns approximately 8% to 9% of Enlivex shares.
The executive chairman described a potential “value loop” in which gains realized by the nonprofit foundation on Enlivex shares could be reinvested in activities intended to expand the RAIN protocol. He said the protocol uses approximately 50% of its profits to purchase and permanently burn RAIN tokens, a mechanism management characterized as deflationary. Enlivex, as a large institutional holder of RAIN, could benefit if the token’s value rises, management said.
RAIN Protocol Update and Risks
Management said the RAIN Foundation provided data showing a 622% increase in trading volume in July compared with June. Novik attributed the increase in part to the launch of version 2 of the protocol, enhanced liquidity and an initial marketing campaign.
Novik emphasized that RAIN remains an early-stage business and that Enlivex does not operate the protocol. He said the foundation has projected gross trading volume of $1.3 billion in 2027, $12 billion in 2028 and $33 billion in 2029. The foundation’s projections call for gross fees of $49 million, $436 million and $1.2 billion in those respective years, as well as up to $600 million in token purchases and burns in 2029.
Management cautioned that these are the foundation’s projections and may not be achieved. In response to questions about the possibility of a sharp decline in RAIN token value, Novik said the company would seek to maintain operations, complete its ongoing clinical trial and position itself to advance toward Phase III development regardless of the treasury’s performance.
He added that Enlivex may consider a more balanced treasury approach over time if RAIN develops greater liquidity, broader exchange listings and further institutional acceptance.
Allocetra Development and RMAT Designation
On the clinical side, Hershkovitz said Allocetra is being developed for knee osteoarthritis, a condition that management said affects 14 million adults in the United States and has limited treatment options beyond pain medication, steroids and joint-replacement surgery.
Enlivex previously reported results from a randomized, double-blind, placebo-controlled Phase I/IIa trial involving 149 patients. Hershkovitz said the study’s primary objective was safety, while efficacy measures included pain and function. He said patients age 60 and older showed statistically significant and clinically meaningful improvements in pain and function at three and six months, alongside a favorable safety profile with no serious adverse events reported.
The company has advanced Allocetra into a Phase IIb study in patients older than 64 with knee osteoarthritis. The randomized, double-blind, placebo-controlled, multicountry study dosed its first U.S. patient in May and continues to recruit patients in the United States and Denmark. Enlivex expects six-month top-line data by mid-2027.
Hershkovitz also said the U.S. Food and Drug Administration granted Allocetra a Regenerative Medicine Advanced Therapy, or RMAT, designation based on the company’s Phase I/IIa data. Enlivex plans to hold a Type B meeting with the FDA to discuss its broader development plan.
According to Hershkovitz, the designation may enable more intensive interactions with the FDA, support earlier discussions of the development strategy and allow for a rolling submission process. He said the designation reinforces management’s decision to focus Phase IIb enrollment on patients older than 64.
About Enlivex Therapeutics (NASDAQ:ENLV)
Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.
The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.
